Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9506
Title: | Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso |
Authors: | McNamee, Nicholas;Harvey, Catriona;Gray, Lauren;Khoo, T.;Lingam, L.;Zhang, B.;Nindra, U.;Yip, P. Y.;Pal, A.;Clay, T.;Arulananda, S.;Itchins, M.;Pavlakis, N.;Kao, S.;Bowyer, S.;Chin, V.;Warburton, L.;Pires da Silva, Ines;John, T.;Solomon, B.;Alexander, M.;Nagrial, Adnan M. |
WSLHD Author: | McNamee, Nicholas;Harvey, Catriona;Gray, Lauren;Pires da Silva, Ines;Nagrial, Adnan M. |
Subjects: | Oncology |
Issue Date: | 2024 |
Citation: | Journal of Thoracic Oncology 19(4):636-642, 2024 |
Abstract: | BACKGROUND: Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-year overall survival of 10%. First-line immunotherapy with ipilimumab and nivolumab is now a standard of care for unresectable pleural mesothelioma following the CheckMate 743 trial, with supportive data from the later line single-arm MAPS2 trial. RIOMeso evaluates survival and toxicity of this regimen in real-world practice. METHODS: Demographic and clinicopathologic data of Australian patients treated with ipilimumab and nivolumab in first- and subsequent-line settings for pleural mesothelioma were collected retrospectively. Survival was reported using the Kaplan-Meier method and compared between subgroups with the log-rank test. Toxicity was investigator assessed using Common Terminology Criteria for Adverse Events version 5.0. RESULTS: A total of 119 patients were identified from 11 centers. The median age was 72 years, 83% were male, 92% had Eastern Cooperative Oncology Group less than or equal to 1, 50% were past or current smokers, and 78% had known asbestos exposure. In addition, 50% were epithelioid, 19% sarcomatoid, 14% biphasic, and 17% unavailable. Ipilimumab and nivolumab were used first line in 75% of patients. Median overall survival (mOS) was 14.5 months (95% confidence interval [CI]: 13.0-not reached [NR]) for the entire cohort. For patients treated first line, mOS was 14.5 months (95% CI: 12.5-NR) and in second- or later-line patients was 15.4 months (95% CI: 11.2-NR). There was no statistically significant difference in mOS for epithelioid patients compared with nonepithelioid (19.1 mo [95% CI: 15.4-NR] versus 13.0 mo [95% CI: 9.7-NR], respectively, p = 0.064). Furthermore, 24% of the patients had a Common Terminology Criteria for Adverse Events grade greater than or equal to 3 adverse events, including three treatment-related deaths. Colitis was the most frequent adverse event. CONCLUSIONS: Combination immunotherapy in real-world practice has poorer survival outcomes and seems more toxic compared with clinical trial data. This is the first detailed report of real-world survival and toxicity outcomes using ipilimumab and nivolumab treatment of pleural mesothelioma. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9506 |
DOI: | https://dx.doi.org/10.1016/j.jtho.2023.11.014 |
Journal: | Journal of Thoracic Oncology |
Type: | Journal Article |
Study or Trial: | Clinical Trial Controlled Study Major Clinical Study Retrospective Study |
Department: | Oncology |
Facility: | Blacktown Westmead |
Affiliated Organisations: | The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia Garvan Institute of Medical Research, Sydney, Australia Sir Charles Gairdner Hospital, Perth, Australia Fiona Stanley Hospital, Perth, Australia Chris O'Brien Lifehouse, Sydney, Australia Liverpool Hospital, Sydney, Australia Campbelltown Hospital, Sydney, Australia St. John of God Subiaco Hospital, Perth, Australia Edith Cowan University, Perth, Australia Monash Health, Melbourne, Australia Monash University, Melbourne, Australia Royal North Shore Hospital, Sydney, Australia University of Sydney, Sydney, Australia University of Western Australia, Perth, Australia University of New South Wales, Sydney, Australia Blacktown Hospital, Sydney, Australia Peter MacCallum Cancer Centre, Melbourne, Australia University of Melbourne, Melbourne, Australia |
Keywords: | immunotherapy lung neoplasms mesothelioma pleura neoplasms asbestos ipilimumab nivolumab |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.